Hosted on MSN5d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Nature3y
Cystic fibrosis population carrier screening: Here at last—Are we ready?
Nevertheless, a general consensus has arisen over the years that the potential public health benefits of CF screening, even if not universally appreciated, were too significant to ignore.
Kaleido Scope6y
Gene Expression Core
To assist, the Core: Performs traditional methods such as PCR and Western blotting to measure CFTR expression Offers novel approaches to CFTR mRNA detection, including digital PCR and emerging ...
Nature3y
Premarital and prenatal screening for cystic fibrosis: Experience in the Ashkenazi Jewish population
Testing was performed by multiplex PCR amplification and allele specific ... Gazit E . Prevalence of cystic fibrosis mutations in Israeli Jews. Genet Test 2001; 5: 47–52. ASHG.
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
precisionmedicineonline5d
FDA Approves New 'Vanza Triple' Cystic Fibrosis Drug From Vertex, Expands Label for Trikafta
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.